CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39

Negative
AI Analysis

Summary

Evercore ISI downgraded Tenax Therapeutics from Outperform to In Line and cut its price target from $39 to $5, reflecting a significant negative reassessment of the company's prospects.

Importance:4/10
Sentiment:
-0.85
analyst_downgradeprice_target_cutrating_change
Related Companies

Read the original article

Published by yahoo_finance on August 11, 2026 11:18 AM

Read Original